Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies

被引：0
|
作者：
Ronald Goldwater
Azra Hussaini
Bill Bosch
Paul Nemeth
机构：
[1] PAREXEL Early Phase Clinical Unit,
[2] Churchill Pharmaceuticals LLC,undefined
来源：
Clinical Pharmacokinetics | 2017年 / 56卷
关键词：
Meloxicam; Abiraterone; Healthy Male Subject; Abiraterone Acetate; Dose Proportionality;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：803 / 813
页数：10
相关论文
共 50 条
  • [21] Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study
    Wang, Yanli
    Deng, Qiaohuan
    Gao, Zhenyue
    Liu, Guangwen
    Su, Zhengjie
    Zhao, Yicheng
    Zhang, Lixiu
    Yang, Haimiao
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [22] Pharmacokinetics and bioequivalence of a molnupiravir tablet formulation compared with the molnupiravir capsule formulation in healthy adult participants-a randomized, open-label, three-period, crossover study
    Fiore, Julie L.
    Jin, Yoon
    Heimbach, Tycho
    Patel, Shruti R.
    Zhao, Tian
    Matthews, Catherine Z.
    Pagnussat, Sandra
    Maas, Brian M.
    Cheng, Mickie H.
    Stoch, S. Aubrey
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2025, 69 (03)
  • [23] A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation
    van Rossem, Koen
    Lowe, Jenny A.
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 : 23 - 31
  • [24] An open-label, randomized, crossover study to evaluate the bioavailability of nanoemulsion versus conventional fat-soluble formulation of cholecalciferol in healthy participants
    Marwaha, Raman Kumar
    Verma, Manish
    Walekar, Ajit
    Sonawane, Rakesh
    Trivedi, Chirag
    JOURNAL OF ORTHOPAEDICS, 2023, 35 : 64 - 68
  • [25] Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520
    Remy B. Verheijen
    Diane A. J. van der Biessen
    Sebastien J. Hotte
    Lillian L. Siu
    Anna Spreafico
    Maja J. A. de Jonge
    Linda C. Pronk
    Filip Y. F. L. De Vos
    David Schnell
    Hal W. Hirte
    Neeltje Steeghs
    Martijn P. Lolkema
    Targeted Oncology, 2019, 14 : 67 - 74
  • [26] Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study
    G. Anderson
    D. Meyer
    C. E. Herrman
    C. Sheppard
    R. Murray
    E. J. Fox
    J. Mathena
    J. Conner
    P. O. Buck
    Journal of Neurology, 2010, 257 : 1917 - 1923
  • [27] A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects
    Acharya, Milin
    Gonzalez, Martha
    Mannens, Geert
    De Vries, Ronald
    Lopez, Christian
    Griffin, Thomas
    NamPhuong Tran
    XENOBIOTICA, 2013, 43 (04) : 379 - 389
  • [28] Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study
    Anderson, G.
    Meyer, D.
    Herrman, C. E.
    Sheppard, C.
    Murray, R.
    Fox, E. J.
    Mathena, J.
    Conner, J.
    Buck, P. O.
    JOURNAL OF NEUROLOGY, 2010, 257 (11) : 1917 - 1923
  • [29] Pharmacokinetics and safety of transdermal and oral granisetron in healthy Chinese subjects: An open-label, randomized, crossover study
    Chen, Rui
    Chen, Xia
    Wang, Hongyun
    Zhong, Wen
    Oh, Eun Sil
    Park, Min Soo
    Kumagai, Yuji
    Zhou, Li
    Nagahama, Fumiko
    Hu, Pei
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (01) : 24 - 31
  • [30] AN OPEN-LABEL, RANDOMIZED, CROSSOVER, COMPARATIVE BIOAVAILABILITY STUDY OF LEVODOPA CYCLOPS® AND INBRIJA® IN HEALTHY ADULT SUBJECTS
    Hoppentocht, M.
    Dijkstra, W.
    Grasmeijer, F.
    PARKINSONISM & RELATED DISORDERS, 2024, 122
12345